China Annual NDA Report Sheds Light On SFDA Thinking, Highlights Pediatric Indications, Orphan Drugs
This article was originally published in PharmAsia News
Executive Summary
China’s State FDA handed out 242 new, and 336 abbreviated new, drug approvals in 2012. Pfizer’s Sutent was one of two products that gained a nod without the need for clinical trials.